In summary, our EAE study results suggest that CX3CL1 and its receptor CX3CR1 may be suitable easily assessed biomarkers of MS-induced NPP that could assist clinicians in the diagnosis and early treatment intervention of MS-induced NPP. This evidence concerns the gene CX3CL1 and myeloid sarcoma.